1. Repatha. https://www.repathahcp.com/ Retrieved on 05, 04, 2023.2. Praluent. https://www.praluent.com/ Retrieved on 05, 04, 2023.3. Leviq. https://www.leqvio.com/ Retrieved on 05, 04, 2023.4. Ballantyne, C. M. et al. Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial. J Am Coll Cardiol. Mar 06, 2023. Epublished DOI: 10.1016/j.jacc.2023.02.0185. Goldstein, J. L. et al. The LDL Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009, 29, 431–438.6. Nishikido, T. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Cardiovascular Diabetology. 2023, 22, 20.7. Abifadel, M. et al. Genetic and molecular architecture of familial hypercholesterolemia. Journal of Internal Medicine. 2023, 293, 144-165.8. Merck’s MK-0616 may become the first oral PCSK9 inhibitor in the dyslipidemia market. Clinical Trials Arena. 09, 03, 2023.9. Grundy, S. M. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC /NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019, 73, 3168-3209.10. Koskinas, K. C. et al. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. European Journal of Preventive Cardiology. 2021, 28, 59–65.11. Tucker, T. J. et al. A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors. J. Med. Chem. 2021, 64, 16770–16800.12. Biopharma Media. Merck & Co. Has Come Up With Very Powerful Pill Against 'Bad’ Cholesterol. 08, 03, 2023.